Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2025 08:18 ET | Source: Research and Markets

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline and Competitive Intelligence Report 2025: Oncology Applications Using Biomarker-driven Patient Stratification and Combination Treatments

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 21, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation

NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
November 20, 2025 11:42 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cellsActivates multiple immune pathways to...
November 20, 2025 09:03 ET | Source: Mordor Intelligence

Anal Cancer Market: Dominated by Squamous Cell Carcinoma at 80.23%; Expected 6.68% CAGR Growth during 2025 - 2030, Reports Mordor Intelligence

Hyderabad, India, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The Anal Cancer Market is valued at USD 0.97 billion in 2025 and is projected to surpass USD 1.34 billion by 2030 at a 6.68% CAGR, supported by...
November 19, 2025 10:34 ET | Source: Research and Markets

Immunology Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties of 900+ Deals by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the report...
November 19, 2025 09:52 ET | Source: Research and Markets

Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Ewing Sarcoma Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
November 18, 2025 04:04 ET | Source: Research and Markets

Rhinitis Market Research Report 2025-2035: Sustained Innovation in Treatment Approaches and Strengthened Therapeutic Capabilities Bolster Expansion

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Rhinitis Market - A Global and Regional Analysis: Focus on Drug Type and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to...
November 18, 2025 03:30 ET | Source: Custom Market Insights

[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)

Austin, TX, USA, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “NUT Midline Carcinoma Treatment Market Size, Trends and Insights By Treatment...
November 17, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of...
November 17, 2025 07:00 ET | Source: https://immatics.com/

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will...